Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23


Exploitation of CD133 for the targeted imaging of lethal prostate cancer.

Glumac PM, Gallant JP, Shapovalova M, Li Y, Murugan P, Gupta S, Coleman I, Nelson PS, Dehm SM, LeBeau AM.

Clin Cancer Res. 2019 Nov 15. pii: clincanres.1659.2019. doi: 10.1158/1078-0432.CCR-19-1659. [Epub ahead of print]


PEG10 Promoter-Driven Expression of Reporter Genes Enables Molecular Imaging of Lethal Prostate Cancer.

Shapovalova M, Lee JK, Li Y, Vander Griend DJ, Coleman IM, Nelson PS, Dehm SM, LeBeau AM.

Cancer Res. 2019 Nov 1;79(21):5668-5680. doi: 10.1158/0008-5472.CAN-19-2181. Epub 2019 Sep 17.


Correction: Exploiting the transcriptional specificity of the alpha-methylacyl-CoA racemase AMACR promoter for the molecular imaging of prostate cancer.

Shapovalova M, Davydova J, Henzler C, Daniel M, Dehm SM, Warlick CA, LeBeau AM.

Oncotarget. 2019 Aug 6;10(47):4920. doi: 10.18632/oncotarget.27143. eCollection 2019 Aug 6.


Development of a Cross-Reactive Monoclonal Antibody for Detecting the Tumor Stroma.

Hintz HM, Cowan AE, Shapovalova M, LeBeau AM.

Bioconjug Chem. 2019 May 15;30(5):1466-1476. doi: 10.1021/acs.bioconjchem.9b00206. Epub 2019 Apr 18.


Exploiting the transcriptional specificity of the alpha-methylacyl-CoA racemase AMACR promoter for the molecular imaging of prostate cancer.

Shapovalova M, Davydova J, Henzler C, Daniel M, Dehm SM, Warlick CA, LeBeau AM.

Oncotarget. 2018 Nov 30;9(94):36693-36704. doi: 10.18632/oncotarget.26401. eCollection 2018 Nov 30. Erratum in: Oncotarget. 2019 Aug 06;10(47):4920.


The Molecular Imaging of Natural Killer Cells.

Shapovalova M, Pyper SR, Moriarity BS, LeBeau AM.

Mol Imaging. 2018 Jan-Dec;17:1536012118794816. doi: 10.1177/1536012118794816. Review.


The role of CD133 in cancer: a concise review.

Glumac PM, LeBeau AM.

Clin Transl Med. 2018 Jul 9;7(1):18. doi: 10.1186/s40169-018-0198-1. Review.


The identification of a novel antibody for CD133 using human antibody phage display.

Glumac PM, Forster CL, Zhou H, Murugan P, Gupta S, LeBeau AM.

Prostate. 2018 Sep;78(13):981-991. doi: 10.1002/pros.23656. Epub 2018 May 22.


The Rational Design of Therapeutic Peptides for Aminopeptidase N using a Substrate-Based Approach.

Joshi S, Chen L, Winter MB, Lin YL, Yang Y, Shapovalova M, Smith PM, Liu C, Li F, LeBeau AM.

Sci Rep. 2017 May 2;7(1):1424. doi: 10.1038/s41598-017-01542-5.


Engineering of Anti-CD133 Trispecific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated Cytotoxicity.

Schmohl JU, Felices M, Oh F, Lenvik AJ, Lebeau AM, Panyam J, Miller JS, Vallera DA.

Cancer Res Treat. 2017 Oct;49(4):1140-1152. doi: 10.4143/crt.2016.491. Epub 2017 Feb 20.


Non-invasive imaging and cellular tracking of pulmonary emboli by near-infrared fluorescence and positron-emission tomography.

Page MJ, Lourenço AL, David T, LeBeau AM, Cattaruzza F, Castro HC, VanBrocklin HF, Coughlin SR, Craik CS.

Nat Commun. 2015 Oct 1;6:8448. doi: 10.1038/ncomms9448.


Imaging active urokinase plasminogen activator in prostate cancer.

LeBeau AM, Sevillano N, Markham K, Winter MB, Murphy ST, Hostetter DR, West J, Lowman H, Craik CS, VanBrocklin HF.

Cancer Res. 2015 Apr 1;75(7):1225-35. doi: 10.1158/0008-5472.CAN-14-2185. Epub 2015 Feb 11.


Protease-activated pore-forming peptides for the treatment and imaging of prostate cancer.

LeBeau AM, Denmeade SR.

Mol Cancer Ther. 2015 Mar;14(3):659-68. doi: 10.1158/1535-7163.MCT-14-0744. Epub 2014 Dec 23.


Imaging the urokinase plasminongen activator receptor in preclinical breast cancer models of acquired drug resistance.

LeBeau AM, Sevillano N, King ML, Duriseti S, Murphy ST, Craik CS, Murphy LL, VanBrocklin HF.

Theranostics. 2014 Jan 18;4(3):267-79. doi: 10.7150/thno.7323. eCollection 2014.


Targeting uPAR with antagonistic recombinant human antibodies in aggressive breast cancer.

LeBeau AM, Duriseti S, Murphy ST, Pepin F, Hann B, Gray JW, VanBrocklin HF, Craik CS.

Cancer Res. 2013 Apr 1;73(7):2070-81. doi: 10.1158/0008-5472.CAN-12-3526. Epub 2013 Feb 11.


Imaging a functional tumorigenic biomarker in the transformed epithelium.

LeBeau AM, Lee M, Murphy ST, Hann BC, Warren RS, Delos Santos R, Kurhanewicz J, Hanash SM, VanBrocklin HF, Craik CS.

Proc Natl Acad Sci U S A. 2013 Jan 2;110(1):93-8. doi: 10.1073/pnas.1218694110. Epub 2012 Dec 17.


Antagonistic anti-urokinase plasminogen activator receptor (uPAR) antibodies significantly inhibit uPAR-mediated cellular signaling and migration.

Duriseti S, Goetz DH, Hostetter DR, LeBeau AM, Wei Y, Craik CS.

J Biol Chem. 2010 Aug 27;285(35):26878-88. doi: 10.1074/jbc.M109.077677. Epub 2010 May 25.


Prostate-specific antigen: an overlooked candidate for the targeted treatment and selective imaging of prostate cancer.

LeBeau AM, Kostova M, Craik CS, Denmeade SR.

Biol Chem. 2010 Apr;391(4):333-43. doi: 10.1515/BC.2010.044. Review.


Molecular insights into substrate specificity of prostate specific antigen through structural modeling.

Singh P, LeBeau AM, Lilja H, Denmeade SR, Isaacs JT.

Proteins. 2009 Dec;77(4):984-93. doi: 10.1002/prot.22524.


Optimization of peptide-based inhibitors of prostate-specific antigen (PSA) as targeted imaging agents for prostate cancer.

LeBeau AM, Banerjee SR, Pomper MG, Mease RC, Denmeade SR.

Bioorg Med Chem. 2009 Jul 15;17(14):4888-93. doi: 10.1016/j.bmc.2009.06.012. Epub 2009 Jun 13.


Targeting the cancer stroma with a fibroblast activation protein-activated promelittin protoxin.

LeBeau AM, Brennen WN, Aggarwal S, Denmeade SR.

Mol Cancer Ther. 2009 May;8(5):1378-86. doi: 10.1158/1535-7163.MCT-08-1170. Epub 2009 May 5.


Prostate-specific antigen is a "chymotrypsin-like" serine protease with unique P1 substrate specificity.

LeBeau AM, Singh P, Isaacs JT, Denmeade SR.

Biochemistry. 2009 Apr 21;48(15):3490-6. doi: 10.1021/bi9001858.


Potent and selective peptidyl boronic acid inhibitors of the serine protease prostate-specific antigen.

LeBeau AM, Singh P, Isaacs JT, Denmeade SR.

Chem Biol. 2008 Jul 21;15(7):665-74. doi: 10.1016/j.chembiol.2008.05.020.

Supplemental Content

Loading ...
Support Center